Quick Answer
Jade Biosciences, Inc. reported Stockholders Equity of $332.52 million for the year ending 2025.
- Jade Biosciences, Inc. showed an increase of +810.5% in Stockholders Equity from 2024 to 2025.
- This data is from Jade Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$5.07 million | Q2 2020: -$7.27 million | Q3 2020: -$9.70 million | Q1 2021: -$16.12 million | Q2 2021: -$21.58 million | Q3 2021: $179.85 million | Q1 2022: $161.95 million | Q2 2022: $151.05 million | Q3 2022: $139.14 million | Q1 2023: $113.10 million | Q2 2023: $141.93 million | Q3 2023: $125.72 million | Q4 2023: $109.46 million | Q1 2024: $90.90 million | Q3 2024: -$16.86 million | Q1 2025: -$83.51 million | Q2 2025: $201.56 million | Q3 2025: $179.35 million.
- Over the full 8 years of available data (2019 to 2025), Jade Biosciences, Inc.'s Stockholders Equity has grown by 9,227.6%.
- Historical annual values: Fiscal year 2025: $332.52 million | Fiscal year 2024: -$46.80 million | Fiscal year 2024: $1.0 thousand | Fiscal year 2023: $109.46 million | Fiscal year 2022: $126.74 million | Fiscal year 2021: $172.42 million | Fiscal year 2020: -$13.34 million | Fiscal year 2019: -$3.64 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: